Drawing for GALEXOS

USPTO serial 85283618

GALEXOS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
LUDEMAN, JESSICA ANN
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with GALEXOS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Brian T. Jaenicke

One Johnson & Johnson PlazaNew Brunswick, NJ 08933UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Human pharmaceuticals for the treatment of infectious-related disease, auto-immune and inflammatory diseases, cardiovascular diseases, central nervous system diseases and pain, dermatologic disorders, metabolic diseases, anti-viral diseases, oncologic diseases, respiratory diseases, ophthalmic diseases, muscle dystonias, wrinkles and smooth muscle disorders, gastro-intestinal diseases; Human pharmaceuticals for use as hemostatic agentsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Nov 10, 2014MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 10, 2014ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 4, 2014EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 3, 2014EX5GSOU EXTENSION 5 GRANTED—
Mar 26, 2014EXT5SOU EXTENSION 5 FILED—
Mar 26, 2014EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 19, 2014ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 19, 2014REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 26, 2013EXRANOTICE OF APPROVAL OF EXTENSION REQUEST MAILED—
Sep 25, 2013EX4GSOU EXTENSION 4 GRANTED—
Sep 23, 2013EXT4SOU EXTENSION 4 FILED—
Sep 23, 2013EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 11, 2013EXRANOTICE OF APPROVAL OF EXTENSION REQUEST MAILED—
Apr 10, 2013EX3GSOU EXTENSION 3 GRANTED—
Apr 10, 2013AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Mar 20, 2013EXT3SOU EXTENSION 3 FILED—
Mar 20, 2013EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 2, 2012EXRANOTICE OF APPROVAL OF EXTENSION REQUEST MAILED—
Oct 1, 2012EX2GSOU EXTENSION 2 GRANTED—
Sep 27, 2012EXT2SOU EXTENSION 2 FILED—
Sep 27, 2012EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 30, 2012EXRANOTICE OF APPROVAL OF EXTENSION REQUEST MAILED—
May 29, 2012EX1GSOU EXTENSION 1 GRANTED—
May 22, 2012IROARESPONSE TO ITU OFFICE ACTION ENTERED—
May 22, 2012FAXXFAX RECEIVED—
May 16, 2012ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
May 4, 2012INCEITU OFFICE ACTION ISSUED FOR EXTENSION REQUEST—
May 2, 2012AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 3, 2012EXT1SOU EXTENSION 1 FILED—
Apr 3, 2012EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 4, 2011NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 9, 2011PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 20, 2011NPUBNOTICE OF PUBLICATION—
Jun 17, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 17, 2011DOCKASSIGNED TO EXAMINER—
Apr 6, 2011NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 5, 2011NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance